Publique un comentario 
Tormenta de citoquinas: Sepsis y Linfohistiocitosis hemofagocítica
Texto completo:
PDFResumen
Resumen
Existen condiciones médicas que constituyen un peligro mortal para los pacientes que las padecen, que reciben diferentes denominaciones y comparten un estado de hiperinflamación caracterizado por la producción exagerada de mediadores de señalización y una asociación de manifestaciones clínicas similares. Para su manejo y tratamiento se involucran diferentes especialidades médicas. Aunque los antimicrobianos son un pilar importante, cuando el origen son las enfermedades infecciosas, estos no constituyen las únicas alternativas para lograr controlar la aparición de estos estados y disminuir la mortalidad asociada.
Abstract
There are medical conditions that constitute a mortal danger for patients who suffer from them. These conditions are named by different ways and share a state of hyperinflammation, characterized by the overproduction of signaling mediators and the association of similar clinical manifestations. Different medical specialties are involved in its management and treatment. Although antimicrobials are an important pillar, when the origin is infectious diseases, these are not the only alternatives to control the appearance of these states and reduce the associated mortality.
Palabras clave
Referencias
Mehta P, Cron RQ, Hartwell J, Manson J, Tattersall RS. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol 2020; 2:358–67.
Lukan N. “Cytokine storm”, not only in COVID-19 patients: mini-review. Immunology Letters 2020; 228:38–44.
Singer M, Deutschman CS, Seymour CW, Shankar- Hari M, Annane D, Bauer M. et. Al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315:801–810.
Krzystek- Korpacka M, Mierzchala M, Neubauer K, Durek G, Gamian A. Midkine, a multifunctional cytokine, in patient with severe sepsis and septic shock: a pilot study. Shock 2011; 35:471-7.
Thompson K, Venkatesh B, Finfer S. Sepsis and septic shock: current approaches to management. Internal Medicine Journal 2019; 49:160–70.
Mostaza- Fernández JL, Guerra- Lazo J, Carriedo- Ule D, Ruiz de Morales JMG. Hemophagocytic lymphohistiocytosis associated with viral infections: Diagnostic challenge and therapeutic dilemma. Rev Clin Esp. 2014; 214:320-7.
Seok- Kim J, Young- LeeJ, Won- Yan J, Hwa- Lee K, Effemberger M, Szpirt W, Krombishler A, et. Al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics 2021; 11:316-29.
Bosmann M, Ward PA. The inflammatory response in sepsis. Trends Immunol. 2013; 34:129–36.
Cai B, Deitch EA, Ulloa L. Novel insights for systemic inflammation in sepsis and hemorrhage. Mediators Inflamm 2010; 2010:642462. Published online 2010 jun 8. doi:10.1155/2010/642462
Feghali CA, Wright TM. Cytokines in acute and chronic inflammation. Frontiers in Bioscience 1997; 2:12-26.
Balk RA, Bone RC. The septic syndrome: definition and clinical implications. Crit Care Clin. 1989; 5:1-8.
Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med. 1989; 17:389-93.
Anas AA, Wiersinga WJ, de Vos AF, van der Poll T. Recent insights into the pathogenesis of bacterial sepsis. The Netherlands Journal of Medicine 2010; 68:147-52.
Opal SM. Concept of PIRO as a new conceptual framework to understand sepsis. Pediatr Crit Care Med 2005; 6: s55-s60.
Cavaillon JM, Adrie C (editores). En Sepsis and Non-infectious Systemic Inflammation. KGaA, Weinheim: WILEY-VCH Verlag GmbH & Co; 2009.
Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM Consensus Conference on sepsis and Organ Failure. Chest 1992; 101:1481-2.
Singer M, Deutschman CS, Seymour CW, Shankar- Hari M, Annane D, Bauer M, Bellomo R, et. al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315:801-10.
Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM Consensus Conference on sepsis and Organ Failure. Chest 1992; 101:1481-2.
Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997; 112:235-43.
Teijaro JR. Cytokine storms in infectious diseases. Semin Immunopathol 2017; 39:501-3.
Scott RB, Robb-Smith AHT. Histiocytic medullary Reticulosis. Lancet 1939; 234:194-8.
Filipovich AH. Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology 2009; 1:127-31.
Henter JI, Horne AC, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et. Al. HLH-2004: Diagnostic and therapeutic gudelines for Hemophagocytic Lymphohistiocytosis. Pediatr Blood Cancer 2007; 48:124-31.
Yu- Ri K, Dae-Young K. Current status of the diagnosis and treatment of hemophagocytic lymphohistiocytosis in adults. Blood Res 2021; 56:S17-S25.
Karakike E, Giamarellos-Bourboulis EJ, Macrophage activation- like syndrome: a distinct entity leading to early death in sepsis. Front Immunol. 10:55. doi: 10.3389/fimmu.2019.00055.
Kyriazopoulou E, Leventogiannis K, Norrby-Teglund A, Dimopoulos G, Pantazi A, Orfanos SE, et. al. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. BMC Medicine (2017) 15:172. DOI 10.1186/s12916-017-0930-5.
Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of Macrophage Activation Syndrome. Front. Immunol 2019; 10: 119.doi: 10.3389/fimmu.2019.00119.
Karki R, Kanneganti TD. The cytokine storm: molecular mechanisms and therapeutic aspects. Trend Immunol 2021; 42:681-705.
Ferrara JL, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin- 1. Transplant Proc 1993; 25:1216-7.
Ferrara JL, Cytokine dysregulation as a mechanism of graft versus gost disease. Curr Opin Immunol 1993; 5:794-9.
AntinJH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80:2964-8.
Behrens EM, Koretzky GA. Cytokine Storm Syndrome: looking toward the precision medicine era. Arthritis & Rheumatology 2017; 69: 1135-43.
Que Y, Hu C, Wan K, Hu P, Wang R, Luo J, et. al. Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. International Rev Immunol 2021; DOI:10.1080/08830185.2021.1884248.
England JT, Abdulla A, Biggs CM, Lee AYY, Hay KA, Hoiland RL, et. al. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. Blood Rev 2020; https://doi.org/10.1016/j.blre.2020.100707.
Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, et. al. Cytokine release syndrome. Journal for Immunotherapy of Cancer 2018; 6:56. https://doi.org/10.1186/s40425-018-0343-9.
Fajgenbaum DC, June CH. Cytokine Storm. NEJM 2020; 383:2255-73.
U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Publish Date: November 27, 2017. Disponible: https://www.meddra.org/.
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed D, Jensen M, et.al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 24:188-95.
Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, et. al. On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis & Rheumatology 2020; 72:1059-63.
Jing Li, Qian Wang, Wenjie Zheng, Jie Ma, Wei Zhang, Wenze Wang, Xinping Tian. Hemophagocytic Lymphohistiocytosis: clinical Analysis of 103 Adult Patients. Medicine 2014; 93:100–5.
Goldman L, Schafer AI (editores). En Goldman- Cecil Medicine. 26 Ed. Elsevier: Philadelphia; 2020.
Gars E, Purington N, Scott G, Chisholm K, Gratzinger D, Martin BA, Ohgami RS. Bone marrow histomorphological criteria can accurately diagnose hemophagocytic lymphohistiocytosis. Haematologica 2018; 103:1635-41.
Chu R, van Eeden C, Suresh S, Sligl WI, Osman M, Tervaert JWC. Do COVID-19 infections result in a different form of secondary Hemophagocytic lymphohistiocytosis. Int. J. Mol. Sci. 2021, 22, 2967. https://doi.org/10.3390/ijms22062967.
Vincent JL, Opal SM, Marshal JC, Tracey KJ. Sepsis definitions: time for change. Lancet 2013; 381: 774–5.
Vincent JL, Moreno R, Takala J, Willats S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, THIJs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996; 22:707-10.
Gabay C, Kushner I. Acute- phase proteins and other systemic responses to inflammation. NEJM 1999; 340:448-54.
Morley JJ, Kushner I. Serum C-reactive protein levels in disease. Ann N Y Acad Sci 1982; 389:406-18.
Wigmore SJ, Fearon KCH, Maingay JP, Lai PBS, Ross JA. Interleukin-8 can mediate acute-phase protein production by isolated human hepatocytes. Am J Physiol 1997; 273:E720-26.
Gauna ME, Bernava JL. Recomendaciones diagnósticas y terapéuticas ante la Respuesta Inmune Trombótica Asociada a COVID-19 (RITAC). CorSalud 2020; 12:60-3.
Parkin J, Cohen B. An overview of the immune system. Lancet 2001; 357:1777–89.
Cruz A. Citoquinas y Receptores en la Interacción hospedero- parásito. Anales de la Facultad de Medicina (Universidad Nacional Mayor de San Marcos) 2000; 61:65-77.
Patel GP, Gurka DP, Balk RA. New treatment strategies for severe sepsis and septic shock. Curr Opin Crit Care 2003; 9:390–6.
Papadakis MA, McPhee SJ (editors). En Current medical diagnosis and treatment. McGrow- Hill Education: New York; 2019.
Tamma PD, Cosgrove SE, Maragakis LL. Combination Therapy for Treatment of Infections with Gram-Negative Bacteria. Clin Microbiol Rev 2012; 25: 450–70.
Kelesidis T, Mastoris I, Metsini A, Tsiodras S. How to approach and treat viral infections in ICU patients. BMC Infectious Diseases 2014, 14:321. http://www.biomedcentral.com/1471-2334/14/321.
Soy M, Atagündüz P, Atagündüz A, Sucak GT. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID‑19 pandemic. Rheumatology International 2021; 41:7-18.
Adamson CS, Chibale K, Goss RJM, Jaspars M, Newman DJ, Dorrington RA. Antiviral drug discovery: preparing for the next pandemic. Chem Soc Rev 2021; 50:3647–55.
Fragkou PC, Moschopoulos CD, Karofylakis E, Kelesidis T, Tsiodras S. Update in viral infections in the Intensive Care Unit. Front. Med. 8:575580. doi: 10.3389/fmed.2021.575580.
Mandell LA, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clinical Infectious Diseases 2003; 37:1405–33.
Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et. al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical Infectious Diseases 2007; 44:S27–72.
Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, et. al. Cytokine storm in COVID-19- immunopathological mechanisms, clinical considerations, and therapeutic approaches: the PROGRAM Consortium Position Paper. Paper. Front. Immunol. 11:1648. doi: 10.3389/fimmu.2020.01648.
Meganck RM, Baric RS. Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases. Nature Medicine 2021; 27:401–10.
Rowaiye AB, Ajiroghene O, Onuh OO, Oloaigbe AJ, Hannah OO, Chidinma OA, et. al. Attenuating the Effects of Novel COVID-19 (SARS-CoV-2) Infection-Induced Cytokine Storm and the Implications. Journal of Inflammation Research 2021; 14:1487–1510.
French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, et.al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med 2021; 47:1181–1247.
Denning NL, Aziz M, Gurien SD, Ping W. DAMPs and NETs in sepsis. Front Immunol 2019; 10:2536. doi: 10.3389/fimmu.2019.02536.
Ling W, Adderley J, Leroy D, Drewny DH, Wilson DW, Kaushansky A, el. Al. Host-directed therapy, an untapped opportunity for antimalarial intervention. Cell Reports Medicine 2021; 2: 100423. doi: 10.1016/j.xcrm.2021.100423.
Kaufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R. Host-directed therapies for bacterial and viral infections. Nature Review 2018; 17:35-56.
Peter AE, Sandeep BV, Rao BG, Kalpana VL. Calming the storm: natural immunosuppressants as adjuvants to target the cytokine storm in COVID-19. Front Pharmacol 2020; 11: 583777. doi: 10.3389/fphar.2020.583777.
Tan XD, Ji TT, Dong JR, Feng H, Chen FQ, Chen X, et. Al. Pathogenesis and treatment of cytokine storm induced by infectious disease. Int J Mol Sci 2021; 22, 13009. https://doi.org/10.3390/ijms222313009.
Kim JS, Lee JY, Yang JW, Lee KH, Effenberger M, Szpirt W, et.al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics 2021; 11: 316-329.
La Rosée P, Horne AC, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, et. al. Recommendation for management of hemophagocytic lymphohistiocytosis in adults. Blood 2019; 133:2465-2477.
D`Elia RV, Harrison K, Oyston PC, Lukaszewski RA, Clark GC. Targeting the cytokine storm for therapeutic benefict. Clinical and Vaccine Immunology 2013; 20:319-27.
Alhazzani W, Moller MH, Arabi YM, Loeb M, Gong MN, Fan E, et. al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med 2020; 46:854–87.
71) Mehta P, McAuley DF, Brown M, Sánchez E, Tattersal RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395:1033-4.
Mehta P, Fajgenbaum DC. Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate. Curr Opin Rheumatol 2021; 33:419–430.
Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology 2019; 58:953-62.
Copyright (c) 2023 Rodolfo Izaguirre Rodríguez
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.
La revista está: Certificada por el CITMA
La revista es de acceso abierto y gratuito.